Hippocampal cholinergic neurostimulating peptide (HCNP), which derives from phosphatidylethanolamine-binding protein (also named Raf kinase inhibitor protein), enhances acetylcholine synthesis in the hippocampal medial septal nuclei. It is present in the chromaffin secretory granules of the adrenal cells and under stress is cosecreted with peptide hormones and catecholamines. Using the isolated rat heart perfused according to Langendorff to reveal the cardiotropic action of HCNP on the mammalian heart, we showed that rat HCNP exerts, at concentrations of 5 ϫ 10 Ϫ13 to 10 Ϫ6 M, a negative inotropism under basal conditions (left ventricular pressure variations ranging from Ϫ8.34 Ϯ 0.94% to Ϫ21 Ϯ 3.5%) and enhances the cholinergic-mediated negative inotropy through direct interaction with G-protein-coupled muscarinic receptor pathway. Under adrenergic stimulation (isoproterenol), the peptide exerts an antiadrenergic action. The analysis of the percentage of rate pressure product variations in terms of EC 50 values of isoproterenol alone (Ϫ8.5 Ϯ 0.3; r 2 ϭ 0.90) and in the presence of rat HCNP at 0.01 nM (Ϫ6.9 Ϯ 0.36; r 2 ϭ 0.88) revealed a competitive type of antagonism of the peptide. HCNP does not affect either heart rate or coronary pressure. The evidence that HCNP in mammals may play a novel role as an inhibitory cardiac modulator throughout an involvement of the myocardial Gprotein-coupled receptor pathway provides new insights regarding the neurohumoral control of heart function under normal and physiopathological conditions. The hippocampal cholinergic neurostimulatory peptide (HCNP) is an undecapeptide named so because it was initially purified from the rat hippocampus and enhanced acetylcholine (ACh) synthesis of medial septal nuclei in an explant culture system (Ojika and Appel, 1984;Ojika et al., 2000). In cholinergic neurons, HCNP exerts dose-dependent and time-dependent increases of both activity and V max of choline acetyltransferase (Ojika et al., 1994), inducing the key enzyme expression required for ACh synthesis and influencing the development of cholinergic phenotypes (Ojika et al., 1994). HCNP is the endogenous N-terminal fragment of the precursor protein phosphatidylethanolamine-binding protein (PEBP), alternatively named Raf-1 kinase inhibitor protein since it interacts with cytoplasmic Raf1 (Yeung et al., 1999). PEBP is ubiquitous, as documented by its occurrence in a wide range of organisms such as bacteria, yeasts, plants, nematodes, Drosophila, and mammals (Schoentgen and Jolles, 1995). It has been shown, particularly in mammals, that members of the PEBP family are involved in several signaling systems, modulate the action of heterotrimeric Gproteins, and inhibit several serine proteases (Hengst et al., 2001) as well as mitogen-activated protein kinase and nuclear factor-B pathways (Vallèe et al., 2003). Studies on the relationships between structural and physicochemical features of HCNP and its precursor highlight an important dual function of this undecapeptide (Vallèe et al., 20...